ALNYLAM PHARMACEUTICALS, INC. Alnylam Pharmaceuticals, Inc. Share Price
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 143.3 USD | -0.28% |
|
-0.76% | -25.13% |
| 08/04 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| 08/04 | Sector Update: Health Care | MT |
| Sales 2024 * | 1.85B 155B | Sales 2025 * | 2.27B 189B | Capitalization | 18.12B 1,511B |
|---|---|---|---|---|---|
| Net income 2024 * | -515M -42.94B | Net income 2025 * | -243M -20.26B | EV / Sales 2024 * | 9.6 x |
| Net cash position 2024 * | 340M 28.31B | Net cash position 2025 * | 599M 49.91B | EV / Sales 2025 * | 7.72 x |
| P/E ratio 2024 * |
-35
x | P/E ratio 2025 * |
-81.8
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alnylam Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -0.28% | ||
| 1 week | -0.76% | ||
| Current month | -4.11% | ||
| 1 month | -5.70% | ||
| 3 months | -20.21% | ||
| 6 months | -7.93% | ||
| Current year | -25.13% |
1 week
141.98
150.27
1 month
141.98159.34
Current year
141.98199.38
1 year
141.98218.88
3 years
117.58242.97
5 years
65.81242.97
10 years
31.38242.97
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 19/16/19 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13/19/13 |
Piyush Sharma
CMP | Compliance Officer | - | 21/22/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18/15/18 |
Charles Sigal
BRD | Director/Board Member | 72 | 22/22/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10/19/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.08% | 1 M€ | 0.00% | - | |
| 4.04% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 143.3 | -0.28% | 479,139 |
| 25/24/25 | 143.7 | -0.06% | 489,265 |
| 24/24/24 | 143.8 | -1.55% | 395,369 |
| 23/24/23 | 146.1 | +0.19% | 543,726 |
| 22/24/22 | 145.8 | +0.96% | 399,984 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
143.3
USD
Average target price
219.9
USD
Spread / Average Target
+53.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.13% | 18.12B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B | |
| -16.98% | 10.07B |
- Stock Market
- Equities
- ALNY Stock
